Videos

In part 5 of this Exclusive Interview, Jamie Uribarri talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about high AGE diets and kidney disease, and the limitations of clinical research.

In part 6 of this Exclusive Interview, Jamie Uribarri talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about whether there is any medication that helps lower AGEs.

In part 7 of this Exclusive Interview, Jamie Uribarri talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about advancements in dialysis technologies and why the pace of change is slow.

In part 8, the conclusion of this Exclusive Interview, Jamie Uribarri talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about kidney disease prevention through preventing the development of type 2 diabetes.

Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.

This Exclusive Interview transcript allows you to read the full conversation between Dr. Jim McDermott and Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA. Dr. McDermott discusses the SGLT-2 research at AstraZeneca, including the CVD-REAL  large outcomes trial.

In this Exclusive Interview, Dr. Jim McDermott talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about AstraZeneca SGLT-2 research, including the CVD-REAL  large outcomes trial.

In part 1 of this Exclusive Interview, Dr. Jim McDermott explains the recent AstraZeneca SGLT2 trials in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 2 of this Exclusive Interview, Dr. Jim McDermott explains what research shows about the the efficacy of SGLT2 inhibitors and their benefit to risk ratio in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

In part 3 of this Exclusive Interview, Dr. Jim McDermott explains the DURATION-8 study of Bydureon and dapagliflozin combo therapy in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.